Cheaper isn't the same as cheap
Today's FT had EssilorLuxottica bouncing, Netflix slipping and a takeover approach for Mobico. We checked eight names against company filings. None cleared 15, with EssilorLuxottica, Netflix and Stryker on 13.
A share that has halved is not automatically a bargain. It becomes one only when the price falls further than the business. Today's FT offered several tests of that idea.
Eyewear bounces, but not to a bargain
EssilorLuxottica shares jumped about 14% after third-quarter sales rose 9% to €7.49bn. Smart-glasses growth slowed to 20%, and North America grew 4.7%. The shares are still about half their November 2025 high, and the Del Vecchio heirs are fighting over Delfin, the family holding company.
EssilorLuxottica: 13/20. Lenses, Ray-Ban and its own shops make a real moat, and the core eyecare business grows above 6% a year. But at about 24 times adjusted earnings and a cash yield under 4%, the price still assumes a lot, debt is about 2 times yearly operating profit before depreciation, and the family feud is a risk we cannot price.
Netflix: a great machine on a slower road
Netflix fell about 6% as revenue growth slowed to 12%. The FT notes a lack of hits, about 1,000 job cuts and new heads of content and film. We read the shareholder letter: operating margin is heading for 31.5% this year, and debt is modest.
Netflix: 13/20. One thing to strip out: a $2.8bn break fee from the failed Warner Bros deal flattered this year's profit and cash. Without it, the shares trade at about 23 times earnings and a 3.4% cash yield. With the US 10-year Treasury above 5%, that leaves little room if viewing time keeps stalling.
Knee robots
John Gapper writes that Stryker's Mako robot has now helped with more than a million knee operations, which lets Stryker sell implants as a bundle. Smith & Nephew, its UK rival, is down 20% in a year, with activist Cevian holding 14%.
Stryker: 13/20. A strong moat and a long record, but about 20 times this year's adjusted earnings and a 4% cash yield is a fair price, not a bargain. A cyber attack in March and a new chief executive from January are worth watching.
Smith & Nephew: 11/20. The cheapest of the medical names, at about 14 times adjusted earnings and a 6% cash yield on guidance. But it cut this year's growth forecast to about 4% and trails in robots.
The rest of the list
Carrefour: 10/20. Under 9 times earnings, but French grocery is a price war with no moat, and the riots forced a guidance cut.
Boeing: 6/20, too hard. The Max 10 approval matters and the backlog is about $715bn, but strip out a one-off $9.7bn gain from selling Jeppesen and it still loses money, burns cash and carries about $26bn of net debt.
NextDC: 6/20, too hard. Shares fell 44% to A$5.35 after power delays at its Melbourne M3 site cut this year's profit guidance by over a third. It plans to spend A$4.5bn to A$5bn this year against about A$255m of operating profit before depreciation.
Mobico: 5/20, too hard, now a deal. A 46p cash approach, which the board is minded to recommend, sits about 16% above today's price. It is not firm, the deadline is 18 November, and more than £1bn of debt must be refinanced. We would not bet on the gap.
Mention only: SpaceX and Tesla boards are studying a merger (SpaceX is private). IFM is buying Associated British Ports for over £10bn, against £2.8bn in 2006. Index providers are reviewing Indonesia and Turkey. Oil output in the Americas is rising, with TotalEnergies and Chevron among the winners. The Russell 2000 is down 10% since mid-August, and about 40% of its members lose money.
Also on our desk (since Tuesday)
- Ally Financial 12/20 (Tuesday evening X sweep): cheap at about 0.92 times tangible book and 8 times earnings, and Berkshire owns it, but it is a lender earning about 13% on tangible equity.
- Exco Resources 12/20, provisional: an unlisted gas producer, 49% owned by Fairfax, scored on the fund manager's figures only.
- Tonies 11/20: the share price already assumes its 2030 plan.
- Wednesday's Value Investors Club check produced no new scores to report.
Nothing cleared 15 today. Several good businesses are cheaper than they were. None is yet cheap enough.
Research only, not investment advice.
Chronicle